Recombinant fusion protein gp41-gp36 recognized by specific antibodies against HIV-1 and HIV-2, had been expressed and purified for the development of a serological screening kit in this study. Serological screening method by enzyme-linked immunosorbent assay (ELISA) with the purified gp41-gp36 was carried out to test the sensitivity and specificity of the protein by serum samples and reference panels from National Institute for the Control of Pharmaceutical and Biological Products (NICPBP), with the sensitivity and specificity found to be 100 and 99.0%, respectively. As the application was concerned, 42 HIV-1 positive,5 HIV-2 positive, and 300 negative human sera had been used, and reliable results had been obtained in comparison with other reference human immunodeficiency virus (HIV) ELISA kits in panels.
INTRODUCTION
Up until 2007, approximate 33.2 million people worldwide were living with Human Immunodeficiency Virus (HIV), 1.2 million people had newly received HIV antiretroviral therapy in 2009, with an increase in the number of people receiving treatment of 30% and an overall number as 13-fold since 2004 (UNAIDS, 2010 . HIV-1 and HIV-2, the major cause of acquired immunodeficiency syndrome (AIDS), were members of the genus Lentivirinae of the Retroviridae family. HIV-1 virions contained two identical copies of ribonucleic acid (RNA), and a number of viral proteins causing antibody response, including products of viral genes env (gp160, *Corresponding author. E-mail: zhenbo.xu@hotmail.com or xhzhao2006@gmail.com gp120 and gp41), gag (p24, 17, 7 and 9) and pol (p32, 66, 51 and 11), which had been employed as detection targets. HIV-2 differed from HIV-1 in its lower pathogenicity and higher level of intrasubtype strain diversity. Enzyme immunoassy still remained the most commonly used screening test for detection of anti-HIV antibodies. The env gene product gp41 and gag or its fragments p15, 17 and 24 had been produced in a wide variety of expression systems, including Escherichia coli (Wingfield et al., 1997) , Saccharomyces cerevisiae (Gach et al., 2007; Parissi et al., 2000) , insect cell (Weissenhorn et al., 1996) , Chinese hamster ovary cells (Gach et al., 2008; Jeffs et al., 2004; Zhang et al., 2001) , etc.
Construction of the vector, expression and purification of the recombinant fusion antigen gp41-gp36, as well as evaluation of the immunoassay performance for using developed ELISA assay for detection of anti-HIV-1 /2 antibodies had been described in this study.
MATERIALS AND METHODS
Extraction of total RNA from HIV-1 infected serum with the long strain of HIV-1 in Trizol reagent (Invitrogen), preparation of cDNA by reverse transcription polymerase chain reaction (RT-PCR) and deoxyribonucleic acid (DNA) from E. coli, electrophoresis determination, as well as cloning and sequencing, had been performed according to the standard protocol or as described in preliminary studies (Xu et al., 2007 (Xu et al., , 2008a (Xu et al., , b, 2009 (Xu et al., , 2010 (Xu et al., , 2011 .
E. coli BL21 (DE3) cells were transformed with the pET-GSTgp41-gp36 plasmid, and recombinant colonies were selected on Luria-Bertani (LB) agar plates containing ampicillin (50 μg/mL). Following transformation, several recombinant colonies were used to inoculate 5 mL LB medium containing ampicillin (50 μg/mL). To optimize the condition of protein expression, E. coli BL21(DE3) cells harboring pET-GST-gp41-gp36 protein were grown in the presence of isopropyl-beta-D-thiogalactopyranoside (IPTG) (0.5 mM) at 37°C and 240 rpm, monitoring with OD600 measurements (Abs 0.6) and one sample removed every hour after induction. The cells were harvested by centrifugation, stored at −80°C or resuspended in Tris-HCl buffer (100 mM Tris-HCl, pH 8.0, and 1 mM EDTA), and disrupted by sonication (three short bursts, about 10 s each, allowing the bacterial suspension to cool on ice after each burst). The proteins and cell debris were separated by centrifugation under 10,000 g for 30 min at 4°C. The soluble fraction was analyzed by SDS-PAGE.
The cells were harvested by centrifugation under 5,000 g for 30 min at 4°C, resuspended in 3 ml cell lysis buffer containing 50 mM Tris-HCl (pH8.0), 1 mM EDTA, 100 mM NaCl, 1 mM phenylmethylsulfonyl fluoride (PMSF) and 0.5 mg/ml lysozyme. After stirring at 4°C for 30 min, 4 mg deoxycholic acid was added and the resulting suspension was incubated at 37°C with occasional stirring until the suspension turned to be viscous. Ten μg/ml DNase I was then added and the mixture was incubated at room temperature for approximate 30 min to obtain clear suspension, followed by centrifugation under 17,000 g for 30 min at 4°C. The pellet, containing inclusion bodies and cell debris, had been washed three times by re-suspending in wash buffer containing 50 mM Tris-HCl (pH8.0), 10 mM EDTA, 100 mM NaCl, 1 mM PMSF and 0.5% Triton X-100. Soluble fusion protein was obtained by stirring the washed inclusion bodies in 1 ml solubilization buffer I (50 mM Tris-HCl with pH 8.0, 10 mM EDTA, 100 mM NaCl, 1 mM PMSF and 8 M urea) for 1 h, and the resulting solution was diluted with 9 volume of solubilization buffer II (50 mM KH2PO4 with pH 10.7, 1 mM EDTA, 50 mM NaCl and 1 mM PMSF). After incubation for 30 min, pH was adjusted to 8.0 and fusion protein had been further incubated for 1 h. Insoluble materials were removed by centrifugation at 17,000 g for 30 min, and the resulting supernatant containing most of the inclusion bodies was then analyzed by sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) (Lian et al., 2009) .
The recombinant protein was purified exploiting its C-terminal 6X His tag by immobilized metal affinity chromatography (IMAC) using a Ni-NTA super flow chelating agarose column. Initially, the column was equilibrated with 20 ml of inclusion body solubilization buffer (pH 8.0). The clear cell supernatant was initially passed through 0.45 μM filter loaded on to the Ni-NTA column, allowed to bind for 20 min, then washing of the column with 50 ml of wash buffer, pH 6.0 containing 10 mM Tris-Cl, 100 mM NaCl, 100 mM NaH2PO4, 1 mM EDTA and 8 M urea. Ultimately the protein bound to the column was eluted by passing 20 ml elution buffer (pH.4.0) containing 10 mM Tris, 100 mM NaCl, 100 mM NaH2PO4 and 8 M urea. Each elutes was collected in 1 ml fractions, and analyzed on 12% SDS-PAGE (Shukla et al., 2009) . To refold the protein, the dialysis method was utilized as described previously, urea was removed from the purified protein fractions by dialysis for 16 h at 4°C against buffer 1 (50 mM Na2HPO4/NaH2PO4, 300 mM NaCl, 3 M urea, 5 mM dithiothreitol) followed by dialysis against buffer 2 (50mM Na2HPO4/NaH2PO4, 300 mM NaCl, 5 mM dithiothreitol) for 16 h at 4°C. The purified protein was stored at −20°C for further analysis (Hans and Sørensen, 2003) .
The specificity and sensitivity of the proteins were evaluated by ELISA technique. Firstly, the purified recombinant protein was coated in 96 well plates with serial dilutions of 64, 32, 16, 8, 4, 2 and 1 μg/mL. The optimum concentration of each antigen for coating was then determined by calculating the immunoreactivity ratio using optical density of the weak positive standard to the optical density of the negative control. To construct the calibration curve, various positive samples with different ODs were utilized as follows: samples with ODs of more than 2.0, between 1.2 and 1.5, between 0.8 and 1.0, slightly more than cut off value around 0.5-0.6 (Mahboudi et al., 2006) . Serum panels consisted of 42 HIV-1 positive samples, 5 HIV-2 positive samples (these positive samples were confirmed by Western Blot previously) and 300 negative samples from blood donor populations, patients with autoimmune diseases, pregnant women, and patients with other viral diseases and some patients with parasitic infections collected in our lab. National Institute for the Control of Pharmaceutical and Biological Products (NICPBP) panel consisted of 48 samples. A total of 20 HIV negative samples (N1-N20), 18 HIV-1 positive samples (P1-P18), 2 HIV-2 positive samples (P19-P20), 6 limited line samples (S1-S6, of which S1 was Serum Matrix) and 2 exactitude samples were included in the present study. Serum samples and NICPBP panels were tested by the developed ELISA method and compared with other reference commercial ELISA kits. The sensitivity and specificity of the developed ELISA were evaluated as described previously (Nikolaeva et al., 2003) .
RESULTS
An amplicon of 681 bp DNA fragment encoding gp41 protein was amplified by RT-PCR using specific designed primers, which had been further confirmed by sequencing (Figure 1 ). This amplified product and synthesized gene was ligated then cloned into the pUC-18 TA cloning vector followed by subcloning in pET-HIS expression vector. Induced protein band of approximately 52 kDa (data not shown) was observed at 1 mM IPTG for 3 h. Purification of the recombinant protein was performed under denaturing condition. The protein was bound to the column then eluted with the pH gradient and was found to be approximately 95% pure by gel analysis. The yield of pure recombinant protein gp41-gp36 was estimated to be 41 mg/L of shake flask culture.
The sensitivity of the developed ELISA was determined to be 100% for 42 anti-HIV-1 antibody positive and 5 anti-HIV-2 antibody positive serum samples (Table 1) . The specificity of test was found to be 99.0% (297/300) for 300 healthy subjects with none of HIV infected. Some types of virus infections diseases were regarded as influential factors affecting the results of HIV ELISA analysis and leading to false-positive reactions, such as hepatitis C virus (HCV), hepatitis B virus (HBV), leishmaniasis, Epstein-Barr virus (EBV), herpes simplex virus type 1 and 2. In this study, the sensitivity and specificity of this established assay were also evaluated by NICPBP panels and compared with other commercial HIV ELISA kits ( Table 2) . As shown by the results, the developed ELISA based on recombinant fusion protein gp41-gp36 had been demonstrated to be sensitive and specific detection assay on HIV, which exhibited advantages in comparison with other commercials HIV ELISA kits among different samples with NICPBP panel.
DISCUSSION
Since 1994, the donated blood in China had been screened for anti-HIVI/II antibody. To assure the quality of the HIV diagnosis kits, every batch had to be evaluated by the control panel. According to the principle used to select the positive and negative specimens for the panel, two concentrated positive specimens (P11 and 12) with the OD (change the abos) values >2.0 and OD of P12 > P11, were also added to the panel as a control of Hook effect (GB et al., 1996; Wai et al., 2002) . The OD values of P12 and 11 were found to be >3.0, and P12 > P11. Criteria for the panel detection included: positive predictive value (PPV) was 100% (with all positive specimens detected to be positive), the OD value of P12 > P11, negative predictive value (NPV) was more than 90% (with at least 18 out of the 20 negative specimens detected to be negative), at least 3 out of the 5 serial dilution specimens detected to be positive and the matrix diluent detected to be negative (You, 2006) . According to the results, the recombinant fusion protein gp41-gp36 based ELISA assay established in this study was in full accordance with the criteria of NICPBP. In addition, the purification procedure to eliminate bacterial contaminants from the fusion protein was found to be reliable and reproducible, indicating that the purified gp41-gp36 by the processing methodology described in the current study may aid in the diagnostic detection of HIV as an antigen for anti-HIV antibodies screening test. 
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